India's anti-cancer drug price cuts to save consumers ₹3,540 crore yearly

India's National Pharmaceutical Pricing Authority has implemented price reductions across 1,364 anti-cancer drug formulations effective this week, following regulatory action by the Department of Pharmaceuticals. The revised maximum retail prices are projected to save consumers approximately ₹3,540.38 crore annually, according to government announcements.

The pricing action stems from recommendations submitted in mid-October by an Expert Committee constituted by the Directorate General of Health Services under the Ministry of Health and Family Welfare. The regulator capped trade margins on 137 anti-cancer drugs to achieve the reductions. As of November 8, a total of 85 pharmaceutical companies had reported revised pricing for the affected formulations across 121 different drugs.

The scale of price reductions is substantial, with 679 brands experiencing cuts exceeding 50 percent. The steepest discount recorded reaches 96.45 percent, the Department of Pharmaceuticals confirmed. The pricing action reflects efforts to improve affordability of cancer treatments across the country, where cost remains a significant barrier to access for many patients.

Pharmacies and hospitals are required to comply with the new maximum retail prices, ensuring consumers benefit from the regulated pricing structure. The government indicated that strict adherence to the revised price caps will be monitored across the distribution chain.